ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

ClinicalTrials.gov ID: NCT04829604

Public ClinicalTrials.gov record NCT04829604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd

Study identification

NCT ID: NCT04829604
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Ambrx, Inc.; Industry
Enrollment: 72 participants

Conditions and interventions

Conditions

HER2 Positive Metastatic Breast Cancer

Interventions

ARX788 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 26, 2021 (Actual)
Primary completion: Dec 2026 (Estimated)
Completion: Jun 2027 (Estimated)
Last update posted: Mar 9, 2026

2021 – 2027

United States locations

U.S. sites: 25
U.S. states: 16
U.S. cities: 25

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90033	—
Research Site	Newport Beach	California	92663	—
Research Site	San Francisco	California	94158	—
Research Site	Whittier	California	90602	—
Research Site	Atlanta	Georgia	30322	—
Research Site	Chicago	Illinois	60611	—
Research Site	Louisville	Kentucky	40207	—
Research Site	Silver Spring	Maryland	20904	—
Research Site	Boston	Massachusetts	02215	—
Research Site	St Louis	Missouri	63110	—
Research Site	Omaha	Nebraska	68130	—
Research Site	Las Vegas	Nevada	89128	—
Research Site	Camden	New Jersey	08103	—
Research Site	New Hyde Park	New York	11042	—
Research Site	New York	New York	10028	—
Research Site	Shirley	New York	11967	—
Research Site	The Bronx	New York	10469	—
Research Site	Portland	Oregon	97213	—
Research Site	Tigard	Oregon	97223	—
Research Site	Philadelphia	Pennsylvania	19104	—
Research Site	Dallas	Texas	75246	—
Research Site	Houston	Texas	77030	—
Research Site	San Antonio	Texas	78229	—
Research Site	Norfolk	Virginia	23502	—
Research Site	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04829604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 9, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04829604 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →